Cellectis (CLLS) Current Deferred Tax Assets (2024)

Cellectis (CLLS) recorded quarterly Current Deferred Tax Assets of $710000.0 in Q2 2024, up 73.59% quarter-over-quarter from $409000.0 in Q1 2024.

Cellectis (CLLS) Current Deferred Tax Assets (2024) Analysis & Trends

Cellectis' Current Deferred Tax Assets history runs 1 years deep, the most recent figure standing at $710000.0 for Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Cellectis	17.40 Bn	17.21 Bn	-

Download Data